Galera Therapeutics Inc (GRTX)

[loanranger]

"Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the first patient has been dosed in a Phase 2a clinical trial of lead product candidate avasopasem manganese (GC4419) to evaluate its ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer."

“Radiation-induced esophagitis is a common, debilitating side effect that can delay or prevent curative cancer treatment, and no FDA-approved therapies to treat it currently exist,” said Lawrence Berk, M.D., Ph.D., Professor of Radiation Oncology at the University of South Florida and lead investigator of the Phase 2a trial.

"Marks expansion of lead product candidate avasopasem manganese into second radiation toxicity indication"

https://www.globenewswire.com/news-release/2020/01/07/1967578/0/en/Galera-Therapeutics-Announces-Dosing-of-First-Patient-in-Phase-2a-Clinical-Trial-of-Avasopasem-Manganese-GC4419-in-Second-Indication.html